TrojAI Announces Strategic Integration with OpenAI's ChatGPT Enterprise Compliance API to Elevate AI Security and Compliance for Enterprises
SAINT JOHN, NB and BOSTON, June 10, 2025 /CNW/ -- TrojAI, the enterprise security platform for artificial intelligence (AI) that protects the behavior of AI models, agents and applications, today announced an integration with OpenAI 's ChatGPT Enterprise Compliance API to deliver enhanced compliance visibility and runtime protection for organizations. This integration brings together two critical pillars of secure AI deployment—security and compliance—into a unified solution, empowering enterprises to scale generative AI (GenAI) use with confidence.
As the adoption of GenAI technologies accelerates across industries, organizations are placing greater focus on managing risks such as unauthorized AI use, prompt injection attacks, data leakage, and regulatory noncompliance. The integration between TrojAI and OpenAI ChatGPT Enterprise Compliance API is designed to support this effort by enabling policy enforcement and comprehensive auditability across enterprise AI interactions.
"By combining OpenAI's enterprise-grade compliance tools with TrojAI's powerful GenAI monitoring and runtime defense capabilities, we're helping organizations strengthen their AI deployments with added layers of security, compliance, and auditability," said Lee Weiner, CEO of TrojAI.
TrojAI's integration with ChatGPT Enterprise Compliance API addresses additional security and compliance requirements around the safe and effective use of AI. TrojAI's integration enables the following across conversations, memories and canvases:
Proactive Detection: Identify and flag high-risk behaviors based on TrojAI policy, including prompt injections, jailbreaks, PII exposure and toxic content designed to prevent potential breaches and data loss.
Compliance Logging: Capture detailed records of prompts, responses and enforcement actions for regulatory and internal audits to enable secure AI use at scale while supporting compliance mandates.
Custom Policy Enforcement: Apply out-of-the-box or organization-specific security and compliance rules to ChatGPT Enterprise activity. This helps ensure ChatGPT is used safely and responsibly within each organization's unique regulatory, legal and operational context.
Integrated Reporting: Deliver user-friendly dashboards and data feeds for compliance, risk and security teams. Integrated reporting turns AI activity into actionable insights, enabling faster decision-making and stronger governance.
This integration enables enterprises to help monitor, enforce and audit AI usage across their ChatGPT Enterprise environments, whether for regulated sectors like finance, healthcare, government, or internal productivity use cases such as HR and sales enablement.
The integration is now available to all ChatGPT Enterprise customers via the TrojAI platform. here.
About TrojAI
TrojAI's mission is to enable the secure rollout of AI in the enterprise. TrojAI delivers a comprehensive security platform for AI that protects AI models, applications and agents. The best-in-class platform empowers enterprises to safeguard AI models, applications and agents both at build time and run time. TrojAI Detect automatically red teams AI models, safeguarding model behavior and delivering remediation guidance at build time. TrojAI Defend is an AI application and agent firewall that protects enterprises from real-time threats at run time. By assessing the risk of AI model behavior during the model development lifecycle and protecting it at run time, TrojAI delivers comprehensive security for AI models, applications and agents.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Nvidia Will Be Wall Street's First $6 Trillion Company, According to One Highly Optimistic Analyst
Roughly three decades ago, the advent and proliferation of the internet began changing corporate America forever. Although it took many years before businesses figured out how to optimize their internet usage to maximize their margins and profits, it became a game-changing technology that helped companies reach new customers. For 30 years, Wall Street and investors have been waiting for the next technological leap that could catapult corporate growth. After a long wait, artificial intelligence (AI) looks to be the answer. With AI, software and systems are given the capacity to make split-second decisions without human assistance. It's a broad-reaching technology that the analysts at PwC believe can increase global gross domestic product by a whopping 26% come 2030. While a laundry list of businesses has benefited from the AI revolution, none has reaped the rewards of this technological leap forward more than semiconductor titan Nvidia (NASDAQ: NVDA). Since the end of 2022, Nvidia's market cap has catapulted from $360 billion to an all-time closing high of $3.76 trillion, as of June 25. But according to one highly optimistic Wall Street analyst, the stock market's AI darling is just warming up and on its way to a greater than $6 trillion valuation. Nvidia has a new highwater price target To be fair, buy ratings are a dime a dozen when it comes to Nvidia. As of June, 66 Wall Street analysts had issued a rating on Nvidia, with a combined 58 listing it as the equivalent of a strong buy or buy. That compares with just one sell rating. However, the June 25 update from Loop Capital analyst John Donovan stands out from the crowd for one particular reason: His and his firm's price target is head and shoulders above everyone else's. Donovan lifted Loop Capital's price target for Nvidia from $175 per share to $250. If Nvidia's share count stays static, we're talking about a $6.1 trillion market cap if Donovan's issued price target is achieved. Nvidia is already the undisputed leader in graphics processing units (GPUs) deployed in AI-accelerated data centers. The company's Hopper (H100) and successor Blackwell GPUs have consistently been backlogged due to overwhelming demand. With demand for AI-GPUs handily outpacing their supply, Nvidia has been able to charge a premium for its hardware, which in turn has sent its gross margin to north of 70%. But Donovan only sees this dominance building. In his note to investors that explained Loop Capital's Street-high price target, Donovan pointed to Nvidia shipping an estimated 6.5 million GPUs this year and 7.5 million next year, with average selling prices for these GPUs topping $40,000. For context, Nvidia has enjoyed a 100% to 300% pricing premium over its AI-GPU direct rivals. More specifically, in speaking with various cloud-service providers, Donovan anticipates that an uptick in data center spending from governments, midsize cloud providers, and startup companies can lead to the next wave of supercharged growth for Nvidia. For instance, CoreWeave 's purchase of 250,000 Hopper chips is the perfect example of startups angling to capitalize on the presumed insatiable demand for compute capacity. The other factor working in Nvidia's favor is that it's been able to grow into its valuation over the last year. Given the company's torrid sales and profit growth, Nvidia is trading at a forward-year earnings multiple of only 27 for fiscal 2027, which will end in January 2027. If Loop Capital's dart throw proves accurate, Nvidia can tip the scales as Wall Street's first $4 trillion, $5 trillion, and $6 trillion business. Loop Capital's optimism overlooks some very tangible headwinds While there's no disputing Nvidia's monopoly-like market share of GPUs being deployed in AI-accelerated data centers, there are a couple of tangible headwinds Donovan appears to be overlooking that can send Nvidia stock in the opposite direction. Arguably the biggest issue for Nvidia is that every game-changing technology and innovation needs ample time to mature, and we're not at that point yet with artificial intelligence. Including the advent of the internet in the mid-1990s, there hasn't been a next-big-thing trend in three decades that's escaped a bubble-bursting event early in its expansion. The fact that most businesses aren't generating a positive return on their AI investments, nor have they optimized their existing AI solutions, suggests that investors have grossly overestimated the early-innings adoption rate and utility of this technology. This bodes poorly for Nvidia stock over the short run. It's also impossible to overlook growing competitive pressure. Don't get me wrong, CEO Jensen Huang's aggressive innovation timeline, which will bring a new advanced GPU to market annually, should have no trouble keeping Nvidia in the lead when it comes to compute potential. But there's more to data center infrastructure than just speed. It can be argued that Nvidia's biggest competitive edge has been the persistent scarcity of AI-GPUs. But with Taiwan Semiconductor Manufacturing ramping up its chip-on-wafer-on-substrate capacity and Advanced Micro Devices upping its production of Instinct series AI-accelerating chips, direct competition is growing. Growing competition is expected to weigh on Nvidia's gross margin. NVDA Gross Profit Margin (Quarterly) data by YCharts. What's more, many of Nvidia's top customers by net sales are internally developing GPUs to use in their data centers. Even though this internally developed hardware trails Nvidia's Hopper and Blackwell in terms of compute potential, it's notably cheaper and more readily accessible (i.e., not backlogged). Internally developed chips could easily take up valuable data-center real estate, delay future upgrade cycles, and pressure Nvidia's gross margin. Lastly, Donovan's research overlooks the sustained priciness of Nvidia stock relative to its trailing-12-month (TTM) sales. Over the past three decades, megacap companies on the leading edge a next-big-thing trend have historically topped out at TTM price-to-sales (P/S) ratios of roughly 30 to 43. Even Nvidia topped out at a TTM P/S multiple of just over 42 last summer. Although the company's rapidly expanding sales has brought this multiple down, it's still tipping the scales at a P/S ratio of almost 26. That's well over double other market-leading "Magnificent Seven" stocks, and history strongly suggests it's not sustainable. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor 's total average return is1,062% — a market-crushing outperformance compared to177%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
Cision Canada
an hour ago
- Cision Canada
Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency of each site. Both facilities undergoing expansions are essential components of Piramal Pharma's integrated antibody-drug conjugate (ADC) offering, ADCelerate™, reflecting the company's commitment to delivering innovative solutions that align with patient needs. Piramal Pharma celebrated the groundbreaking of the expansion of its sterile injectables development and manufacturing facility on June 25, 2025. MUMBAI, India, June 30, 2025 /CNW/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), recently announced a $90M investment plan to expand two of its U.S. facilities, which are critical to its integrated offering. This ambitious investment underscores the company's commitment to industry leadership through continuous growth and innovation. The two sites involved in the expansion are: Riverview, Michigan: The Riverview site provides comprehensive drug substance development and manufacturing services, including specialized solutions for high potency APIs (HPAPIs). This facility is a vital element of ADCelerate™, supplying the payload-linkers essential to the overall safety, stability, and efficacy of ADC therapies. The expansion will add a commercial-scale suite specifically designed for the development and manufacturing of payload-linkers, which is expected to be operational by the end of 2025. Lexington, Kentucky: The Lexington site is Piramal Pharma's dedicated fill/finish facility, specializing in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. As a critical component of Piramal Pharma's integration, the site provides fill/finish services for all integrated programs, including ADCelerate™ projects. The expansion will add commercial-scale sterile injectable manufacturing capabilities with 24,000 additional square feet of manufacturing space, a new laboratory, and state-of-the-art machinery, including a new filling line, two commercial-size lyophilizers, a specialized capping machine, and an external vial washer. The expansion is expected to be completed by late 2027. Piramal Pharma recently broke ground on the expansion plan for its Lexington, Kentucky facility. To celebrate this important milestone and the future growth it signifies for the company, Piramal Pharma hosted a groundbreaking ceremony at the facility on June 25, 2025. This investment comes at a pivotal moment for the sterile injectables market, which is experiencing significant growth driven by increased medical necessity, broader regulatory approvals, and sizable advancements in scientific research and development. Additionally, the streamlined delivery systems associated with sterile injectables contribute to their efficacy and safety, making these solutions increasingly popular among both healthcare providers and patients. Similarly, ADC therapies are gaining substantial traction, fueled by ongoing innovation, wider regulatory acceptance, and robust evidence demonstrating their effectiveness. The growing prevalence of ADCs underscores the pressing need for expanded manufacturing and development capabilities to meet the evolving landscape of patient care. This investment positions Piramal Pharma to capitalize on these trends, ensuring the company can meet the rising demand for both sterile injectables and ADC therapies while enhancing its competitive edge in the market. Upon completion of the expansion in late 2027, the Lexington site will more than double its manufacturing capacity, increasing from 104 product batches per year (at peak utilization) to over 240 annual batches. "We prioritize patient, consumer, and customer centricity in all our operations, engaging with the populations we serve to better understand, anticipate, and address their needs. Our research has revealed that the sterile injectables market is projected to exceed $20B by 2028, underscoring the urgent need for us to enhance our offerings in this segment. We are confident that this strategic $90M investment will empower us to meet the demands of this market, reinforcing our position as a trusted global partner in biologic manufacturing. By enhancing the services we provide to our partners, we can reduce the burden of disease for more patients around the globe," said Nandini Piramal, Chairperson, Piramal Pharma. "As the market adjusts and preferences shift, we are committed to adapting to meet its current requirements," said Peter DeYoung, Chief Executive Officer, Piramal Global Pharma. "ADCs are rapidly emerging as one of the most effective classes of precision immunotherapy targeting certain cancers and tumors. As this class of drugs becomes more prevalent, we will adapt our services to accommodate this growing demand. By investing in the Lexington and Riverview facilities, we will enhance our integrated ADC offering, ADCelerate™, and increase our capacity to bring high-quality, innovative treatments to our clients and their patients worldwide." The Lexington facility expansion also represents an investment in the local community, creating 40 new full-time jobs that will enhance the local economy and strengthen Piramal Pharma's workforce. Piramal Pharma will continue to work alongside local partners, leveraging the region's strengths to remain at the forefront of innovation. Additionally, this investment aligns with the growing trend toward U.S. onshore manufacturing, reinforcing the company's dedication to domestic production in the U.S. and supply chain resilience. At the groundbreaking ceremony, Lexington Mayor Linda Gorton expressed her excitement about the project and the promising opportunities it presents for the city, stating, "Piramal's decision to expand its facility here in Lexington sends a message around the world that Lexington is a great place to do business. Lexington is home to one of the nation's best pharmacy programs – the University of Kentucky College of Pharmacy – and we are well on our way to becoming a leader in the pharmaceutical industry, as well." Others echoed Mayor Gorton's sentiment with equal enthusiasm, including Jim Stephanou, CEO of IPS-Integrated Project Services, who said, "IPS is a proud supporter of Piramal's growth over the past five years, providing fit-for-purpose solutions on transformative projects across India, the UK, Canada, and the U.S. Our longstanding relationship is built on trust and a relentless commitment to technical excellence. Nothing is more rewarding than seeing shovels in the ground, especially here in Lexington. This groundbreaking highlights our deep expertise in Aseptic Fill/Finish facilities, and our passion to help Piramal bring this advanced manufacturing facility to life to deliver critical therapies to patients around the world." Commerce Lexington President and CEO, Bob Quick, said, "We are proud to celebrate this milestone moment with Piramal and excited for its continued growth and success. Biotech is a key strategic target for Greater Lexington economic development professionals, and this expansion will further strengthen the region as a hub for biotech and life sciences. Piramal's investment highlights the advantages of the area as an exceptional place where innovative companies come to grow and thrive." Piramal Pharma Solutions' $90M investment in its U.S. facilities represents a significant advancement in its manufacturing capabilities and underscores its ongoing commitment to patient-centric care. This strategic move will enable Piramal Pharma to meet the evolving needs of the healthcare landscape, positioning the company at the forefront of the rapidly growing sterile injectables and ADC markets and ensuring a brighter future for patients and communities alike. About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. About Piramal Pharma Limited Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. * Includes one facility via PPL's minority investment in Yapan Bio.
Cision Canada
2 hours ago
- Cision Canada
Regensburg Netz GmbH Launches Six-Year Grid Expansion with Corinex Solutions for Grid Visibility
VANCOUVER, BC and REGENSBURG, Germany, June 30, 2025 /CNW/ - In a decisive step toward the digitalization of its energy infrastructure, Regensburg Netz GmbH has signed a long-term contract with Corinex, a global leader in broadband over power line (BPL) technology. The aim of the partnership is to build a powerful communications network for connecting smart meters. Over the next six years, Corinex's BPL technology will be rolled out across the entire grid. This represents a significant milestone in the digital transformation of the electricity network and will enhance both efficiency and grid visibility. Rethinking Energy with BPL Technology At the heart of the grid digitalization lies Corinex's advanced BPL technology. This state-of-the-art communication solution uses the existing power grid to transmit data at high speeds—without requiring additional telecommunications infrastructure in the low-voltage grid. With real-time data transmission capabilities, BPL plays a central role in the development of smart grids by providing the communications foundation for real-time monitoring and control in the low-voltage network. Integrating advanced technologies for the modernization and digitalization of the grid will significantly boost operational efficiency in Regensburg and the surrounding region. The near real-time grid visibility and control enabled by Corinex's solutions allow Regensburg Netz GmbH to optimize energy distribution and enhance grid resilience. This improved visibility helps meet growing demands from the integration of electric vehicles and renewable energy sources into the existing power grid. It is a key enabler of future grid flexibility, supporting better load balancing and reducing the risk of outages through the future controllability of flexible loads and distributed generation. Pilot Project Successfully Completed – Next Phase Underway Following the successful completion of the pilot project in May 2025, Regensburg Netz GmbH is now preparing for the next phase of implementation. The pilot project confirmed the performance and practical applicability of Corinex's BPL solution and underscored its suitability for large-scale deployment. Based on these positive results, the grid operator in Regensburg is now moving forward with confidence into the full rollout phase. Benefits for Grid Operators and Consumers For Regensburg Netz GmbH, the integration of Corinex's BPL technology brings a significant improvement in grid visibility—through real-time insights into the entire network. The system's advanced sensor functions—including voltage monitoring, temperature measurement, and harmonic analysis—enable grid optimization, fast fault detection, and more efficient load management. With the increasing number of electric vehicles and decentralized generation systems, this infrastructure is critical to the grid's stability and efficiency. Environmental Impact and Long-Term Outlook The project aligns with Regensburg's commitment to reducing CO₂ emissions and optimizing energy consumption. With the rising number of electric vehicles and renewable energy sources on the grid, the city's BPL-based smart meters enable better load management, reduced energy losses, and a more flexible, cleaner electricity network. This forward-looking strategy directly supports the achievement of the city's climate goals. Project Timeline and Outlook The smart meter rollout will be implemented in stages—starting with the recently completed pilot installation and continuing with a citywide deployment to be completed by 2030. This phased approach ensures that the technology integrates smoothly into the existing energy infrastructure, minimizing disruptions for utilities and households. About Corinex Corinex is a global leader in broadband over power line (BPL) technology, specializing in solutions for grid visibility and flexibility. Leveraging the standard, Corinex enables utilities to transmit high-speed data over existing power lines, reducing the need for extensive telecom infrastructure. Its solutions are deployed in large-scale projects across Europe to support the integration of renewable energy and the growing demand for electric vehicle charging infrastructure. About Regensburg Netz GmbH Regensburg Netz GmbH operates the electricity and gas grids for Regensburg and the surrounding region, ensuring reliable energy supply for over 250,000 people. As a subsidiary of REWAG Regensburger Energie- und Wasserversorgung AG & Co. KG, the company has played a key role in the region's energy infrastructure since its founding in 2006. In line with the energy transition, Regensburg Netz GmbH is investing heavily in sustainable and intelligent networks to address the challenges of integrating renewable energy and rising e-mobility. Collaborations with research institutions also drive innovation to ensure the network meets future demands. Ensuring supply security remains one of the top priorities, reflecting the company's commitment to improving quality of life and supporting the economic strength of Regensburg and its region.
